Correction: Aptamer AS1411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer
Yuejie Zhu, Xiang Li, Qi Zhang, Xiantao Yang, Xudong Sun, Yi Pan, Xia Yuan, Yuan Ma, Bo Xu, Zhenjun Yang
TL;DR
This paper corrects a previous study about the aptamer AS1411 and its interaction with a complex in drug-resistant lung cancer.
Contribution
The correction addresses errors in the original study's findings and interpretations.
Findings
The original study's claims about AS1411's interaction with the KRAS promoter/hnRNP A1 complex are corrected.
The revised analysis clarifies the aptamer's potency against drug-resistant lung cancer.
Abstract
Correction for ‘Aptamer AS1411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer’ by Yuejie Zhu et al., RSC Med. Chem., 2024, https://doi.org/10.1039/d3md00752a.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
- —National Science and Technology Major Project10.13039/501100018537
- —National Natural Science Foundation of China10.13039/501100001809
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSynthesis and Biological Evaluation · RNA modifications and cancer
The authors regret that the title of their manuscript showed an error. “AS411” should be “AS1411”. The correct title is shown above.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
Supplementary Material